Izrael - hebrejski - Ministry of Health

teva pharmaceutical industries ltd, israel - furosemide - טבליה - furosemide 40 mg - furosemide - furosemide - edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. adjunctive therapy in acute pulmonary edema. treatment of hypertension.

Izrael - hebrejski - Ministry of Health

teva pharmaceutical indust.ltd - furosemide 20 mg / 2 ml - solution for injection - furosemide - parenteral treatment of edema. adjuctive therapy in acute pulmunary edema.

Izrael - hebrejski - Ministry of Health

taro pharmaceutical industries ltd - glyceryl trinitrate 1 mg/ml - solution for infusion - glyceryl trinitrate - control of hypertension during cardiac surgery. unresponsive congestive heart failure associated with acute myocardial infarction. treatment of angina pectoris in hospitalised patients who have not responded to organic nitrates and/or beta blockers. maintenance of controlled hypotension during surgical procedures.

Izrael - hebrejski - Ministry of Health

teva pharmaceutical industries ltd, israel - atenolol - טבליה - atenolol 100 mg - atenolol - atenolol - management of angina pectoris and hypertension,including hypertension of renal origin. late intervention after acute myocardial infarction.

Izrael - hebrejski - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

Izrael - hebrejski - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 20 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

Izrael - hebrejski - Ministry of Health

rekah pharmaceutical industry ltd, israel - prednisone - טבליה - prednisone 20 mg - prednisone - prednisone - anti-inflammatory for treatment of inflammation responsive to glucocorticosteroids such as: acute allergies, rheumataid arthritis.

Izrael - hebrejski - Ministry of Health

teva pharmaceutical indust.ltd - metronidazole 250 mg - tablets - metronidazole - for the treatment of : - symptomatic trichomoniasis in women and men when the presence of the trichomonad has been confirmed by appropriate laboratory procedures. - asymptomatic trichomoniasis in women when the organism is associated with endocervicitis cervicitis or cervical erosion. - asymptomatic consort. - acute intestinal amebiasis (amebic dysentery) and amebic liver absess. - anaerobic bacterial infections caused by susceptible anaerobic bacteria.

Izrael - hebrejski - Ministry of Health

teva pharmaceutical indust.ltd - valaciclovir hydrochloride (as dihydrate) 500 mg - film coated tablets - valaciclovir - valaciclovir teva is indicated for the treatment of herpes zoster (shingles) in immunocompetent adults . valaciclovir teva accelerates the resolution of pain, it reduces the duration, and the proportion of patients with zoster-associated pain, which includes acute and post-herpetic neuralgia. the efficacy of valaciclovir teva in immunocompromised patients has not been established. - valaciclovir teva is indicated for the treatment of the initial and recurrent genital herpes due to herpes simplex infection. - valaciclovir is indicated for the prevention (suppression) of recurrent herpes simplex infections (herpes genitalis). - prophylaxis of cytomegalovirus infection and disease, following organ transplantation. - for the treatment of cold sores (herpes labialis).

Izrael - hebrejski - Ministry of Health

teva pharmaceutical industries ltd, israel - ibuprofen - טבליה - ibuprofen 400 mg - ibuprofen - ibuprofen - for the treatment of rheumatoid arthritis and osteoarthritis, it is indicated both in the treatment of acute flares and in the longterm management of these diseases. for the relief of mild to moderate pain and for the treatment of primary dysmenorrhea.